Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
487 questions in 49 reviews · Breast Cancer
current versionsNo studies 44 · 9%Ungraded 14 · 2.9%Very low 108 · 22.2%Low 128 · 26.3%Moderate 107 · 22%High 86 · 17.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Any O‐BCS vs mastectomy Cumulative local recurrence rate · women with primary breast cancer Oncoplastic breast‐conserving surgery for women with primary breast cancer (2021) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Intervention NR Overall survival · overweight and obese breast cancer survivors Body weight management in overweight and obese breast cancer survivors (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Breast cancer recurrence · overweight and obese breast cancer survivors Body weight management in overweight and obese breast cancer survivors (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Change in body weight · overweight and obese breast cancer survivors Body weight management in overweight and obese breast cancer survivors (2020) · Cochrane | no estimate extracted | 13 studies · 1526 participants | Low |
Intervention NR Change in BMI · overweight and obese breast cancer survivors Body weight management in overweight and obese breast cancer survivors (2020) · Cochrane | no estimate extracted | 11 studies · 1187 participants | Low |
Intervention NR Change in waist circumference · overweight and obese breast cancer survivors Body weight management in overweight and obese breast cancer survivors (2020) · Cochrane | no estimate extracted | 8 studies · 1021 participants | Low |
Intervention NR Disease‐free survival ‐ not reported · overweight and obese breast cancer survivors Body weight management in overweight and obese breast cancer survivors (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · overweight and obese breast cancer survivors Body weight management in overweight and obese breast cancer survivors (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Change in quality of life ‐ overall scales · overweight and obese breast cancer survivors Body weight management in overweight and obese breast cancer survivors (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Breast cancer recurrence · overweight and obese breast cancer survivors Body weight management in overweight and obese breast cancer survivors (2020) · Cochrane | RR 1.95 [0.68, 5.6] | 4 studies · 281 participants | Low |
Intervention NR Change in body weight · overweight and obese breast cancer survivors Body weight management in overweight and obese breast cancer survivors (2020) · Cochrane | no estimate extracted | 21 studies · 1751 participants | Low |
Intervention NR Change in BMI · overweight and obese breast cancer survivors Body weight management in overweight and obese breast cancer survivors (2020) · Cochrane | no estimate extracted | 17 studies · 1353 participants | Low |
Intervention NR Change in waist circumference · overweight and obese breast cancer survivors Body weight management in overweight and obese breast cancer survivors (2020) · Cochrane | no estimate extracted | 13 studies · 1193 participants | Low |
Intervention NR Disease‐free survival · overweight and obese breast cancer survivors Body weight management in overweight and obese breast cancer survivors (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · overweight and obese breast cancer survivors Body weight management in overweight and obese breast cancer survivors (2020) · Cochrane | RR 0.94 [0.76, 1.17] | 4 studies · 394 participants | High |
Intervention NR Change in quality of life ‐ overall scales · overweight and obese breast cancer survivors Body weight management in overweight and obese breast cancer survivors (2020) · Cochrane | no estimate extracted | 10 studies · 867 participants | Low |
Intervention NR Overall survival · overweight and obese breast cancer survivors Body weight management in overweight and obese breast cancer survivors (2020) · Cochrane | no estimate extracted | NR | No studies |
Exercise therapies vs standard care Overall change in worst pain scores · women with aromatase inhibitor‐induced musculoskeletal symptoms (AIMSS) Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early… (2020) · Cochrane | no estimate extracted | 4 studies · 284 participants | Very low |
Exercise therapies vs standard care Overall change in stiffness scores · women with aromatase inhibitor‐induced musculoskeletal symptoms (AIMSS) Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early… (2020) · Cochrane | no estimate extracted | 1 study · 53 participants | Low |
Exercise therapies vs standard care Overall change in grip strength · women with aromatase inhibitor‐induced musculoskeletal symptoms (AIMSS) Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early… (2020) · Cochrane | no estimate extracted | 1 study · 83 participants | Very low |
Exercise therapies vs standard care Overall change in health‐related quality of life · women with aromatase inhibitor‐induced musculoskeletal symptoms (AIMSS) Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early… (2020) · Cochrane | no estimate extracted | 2 studies · 123 participants | Very low |
Exercise therapies vs standard care Overall change in cancer‐specific quality of life · women with aromatase inhibitor‐induced musculoskeletal symptoms (AIMSS) Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early… (2020) · Cochrane | no estimate extracted | 2 studies · 136 participants | Very low |
Exercise therapies vs standard care Adverse effects secondary to the intervention · women with aromatase inhibitor‐induced musculoskeletal symptoms (AIMSS) Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early… (2020) · Cochrane | no estimate extracted | 4 studies · 331 participants | Low |
Exercise therapies vs standard care Adherence to aromatase inhibitors · women with aromatase inhibitor‐induced musculoskeletal symptoms (AIMSS) Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early… (2020) · Cochrane | OR 2.43 [0.41, 14.63] | 2 studies · 224 participants | Very low |
Indocyanine Green Angiography (ICGA) vs clinical evaluation Mastectomy skin flap necrosis (number of women with mastectomy skin flap necrosis within 30 days after surgery) · women undergoing immediate breast reconstruction following mastectomy Indocyanine green angiography for preventing postoperative mastectomy skin flap necrosis in immediate breast… (2020) · Cochrane | RR 0.79 [0.4, 1.56] | 3 studies · 573 participants | Very low |
Indocyanine Green Angiography (ICGA) vs clinical evaluation Infection (number of breasts with infection within 30 days after surgery) · women undergoing immediate breast reconstruction following mastectomy Indocyanine green angiography for preventing postoperative mastectomy skin flap necrosis in immediate breast… (2020) · Cochrane | RR 0.65 [0.44, 0.97] | NR | Very low |
Indocyanine Green Angiography (ICGA) vs clinical evaluation Haematoma (number of breasts with haematoma within 30 days after surgery) · women undergoing immediate breast reconstruction following mastectomy Indocyanine green angiography for preventing postoperative mastectomy skin flap necrosis in immediate breast… (2020) · Cochrane | RR 1.53 [0.47, 4.95] | NR | Very low |
Indocyanine Green Angiography (ICGA) vs clinical evaluation Seroma (number of breast with seroma within 30 days after surgery) · women undergoing immediate breast reconstruction following mastectomy Indocyanine green angiography for preventing postoperative mastectomy skin flap necrosis in immediate breast… (2020) · Cochrane | RR 0.71 [0.37, 1.35] | NR | Very low |
Indocyanine Green Angiography (ICGA) vs clinical evaluation Reoperation (number of women that were operated again within 30 days after surgery) · women undergoing immediate breast reconstruction following mastectomy Indocyanine green angiography for preventing postoperative mastectomy skin flap necrosis in immediate breast… (2020) · Cochrane | RR 0.5 [0.35, 0.72] | 4 studies · 613 participants | Very low |
Indocyanine Green Angiography (ICGA) vs clinical evaluation Dehiscence (number of women with dehiscence within 30 days after surgery). · women undergoing immediate breast reconstruction following mastectomy Indocyanine green angiography for preventing postoperative mastectomy skin flap necrosis in immediate breast… (2020) · Cochrane | RR 4 [0.45, 35.45] | 1 study · 368 participants | Very low |
Indocyanine Green Angiography (ICGA) vs clinical evaluation Infection (number of women with infection of the skin flap or implant within 30 days after surgery) · women undergoing immediate breast reconstruction following mastectomy Indocyanine green angiography for preventing postoperative mastectomy skin flap necrosis in immediate breast… (2020) · Cochrane | RR 0.91 [0.6, 1.4] | 4 studies · 613 participants | Very low |
Indocyanine Green Angiography (ICGA) vs clinical evaluation Haematoma (number of women with haematoma within 30 days after surgery) · women undergoing immediate breast reconstruction following mastectomy Indocyanine green angiography for preventing postoperative mastectomy skin flap necrosis in immediate breast… (2020) · Cochrane | RR 0.87 [0.3, 2.53] | 2 studies · 459 participants | Very low |
Indocyanine Green Angiography (ICGA) vs clinical evaluation Seroma (number of women with seroma within 30 days after surgery) · women undergoing immediate breast reconstruction following mastectomy Indocyanine green angiography for preventing postoperative mastectomy skin flap necrosis in immediate breast… (2020) · Cochrane | RR 1.68 [0.41, 6.8] | 2 studies · 408 participants | Very low |
Indocyanine Green Angiography (ICGA) vs clinical evaluation Mastectomy skin flap necrosis (number of breasts with mastectomy skin flap necrosis within 30 days after surgery) · women undergoing immediate breast reconstruction following mastectomy Indocyanine green angiography for preventing postoperative mastectomy skin flap necrosis in immediate breast… (2020) · Cochrane | RR 0.62 [0.48, 0.82] | NR | Very low |
Indocyanine Green Angiography (ICGA) vs clinical evaluation Reoperation (number of breasts that needed to be operated again within 30 days after surgery) · women undergoing immediate breast reconstruction following mastectomy Indocyanine green angiography for preventing postoperative mastectomy skin flap necrosis in immediate breast… (2020) · Cochrane | RR 0.65 [0.47, 0.92] | NR | Very low |
Indocyanine Green Angiography (ICGA) vs clinical evaluation Dehiscence ‐ not reported · women undergoing immediate breast reconstruction following mastectomy Indocyanine green angiography for preventing postoperative mastectomy skin flap necrosis in immediate breast… (2020) · Cochrane | no estimate extracted | NR | No studies |
OFS vs no OFS Overall survival (OS) Median · women with early breast cancer Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer (2020) · Cochrane | HR 0.86 [0.78, 0.94] | 11 studies · 10374 participants | High |
OFS vs no OFS Disease‐free survival (DFS) Median · women with early breast cancer Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer (2020) · Cochrane | HR 0.83 [0.77, 0.9] | 10 studies · 8899 participants | High |
OFS vs no OFS Toxicity ‐ hot flushes (a combination of "grade 3/4" and "any grade" toxicity) · women with early breast cancer Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer (2020) · Cochrane | RR 1.6 [1.41, 1.82] | 6 studies · 5581 participants | Low |
OFS vs no OFS Toxicity ‐ mood · women with early breast cancer Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer (2020) · Cochrane | no estimate extracted | 7 studies · 5354 participants | Moderate |
OFS vs no OFS Toxicity ‐ bone health (osteoporosis defined by a T score < ‐2.5) · women with early breast cancer Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer (2020) · Cochrane | RR 1.66 [1.1, 2.5] | 1 study · 2011 participants | Low |
OFS vs no OFS Contralateral breast cancer · women with early breast cancer Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer (2020) · Cochrane | RR 0.75 [0.57, 0.97] | 8 studies · 7856 participants | Moderate |
OFS vs no OFS Quality of life · women with early breast cancer Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer (2020) · Cochrane | no estimate extracted | 5 studies · 2996 participants | Low |
Platinum vs non‐platinum regimens Overall survival (OS) · women with metastatic triple‐negative breast cancer (mTNBC) Platinum‐containing regimens for triple‐negative metastatic breast cancer (2020) · Cochrane | HR 0.85 [0.73, 1] | 6 studies · 958 participants | Moderate |
Intervention NR Treatment discontinuation due to adverse event (safety population) · women with metastatic triple‐negative breast cancer (mTNBC) Platinum‐containing regimens for triple‐negative metastatic breast cancer (2020) · Cochrane | RR 0.88 | 5 studies · 843 participants | Moderate |
Platinum vs non‐platinum regimens Progression‐free survival/time to progression (PFS/TTP) · women with metastatic triple‐negative breast cancer (mTNBC) Platinum‐containing regimens for triple‐negative metastatic breast cancer (2020) · Cochrane | HR 0.77 [0.68, 0.88] | 8 studies · 1077 participants | Very low |
Platinum vs non‐platinum regimens Objective tumour response rate (OTRR) (assessable participants) · women with metastatic triple‐negative breast cancer (mTNBC) Platinum‐containing regimens for triple‐negative metastatic breast cancer (2020) · Cochrane | RR 1.4 [1.22, 1.59] | 10 studies · 1205 participants | Low |
Intervention NR Treatment‐related death (safety population) · women with metastatic triple‐negative breast cancer (mTNBC) Platinum‐containing regimens for triple‐negative metastatic breast cancer (2020) · Cochrane | RR 1.06 | 5 studies · 843 participants | Low |
Intervention NR Nausea/vomiting* grade 3 or 4 (safety population) · women with metastatic triple‐negative breast cancer (mTNBC) Platinum‐containing regimens for triple‐negative metastatic breast cancer (2020) · Cochrane | RR 4.77 | 3 studies · 655 participants | Low |
Intervention NR Nephrotoxicity (safety population) · women with metastatic triple‐negative breast cancer (mTNBC) Platinum‐containing regimens for triple‐negative metastatic breast cancer (2020) · Cochrane | no estimate extracted | NR | No studies |